Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release
  1. March 23, 2026

    Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 22, 2026   Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutica...

    View more
  2. March 19, 2026

    Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 19, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutica...

    View more
  3. March 09, 2026

    Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

    Cambridge, MA, Rotterdam, NL, Shanghai, CN —March 9, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the ...

    View more
  4. February 23, 2026

    Harbour BioMed Announces License Agreement and Equity Partnership for a Clinical Stage Antibody

    Cambridge, MA, Rotterdam, NL, Shanghai, CN —February 22, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to ...

    View more
  5. February 04, 2026

    Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 3, 2026   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...

    View more
  6. January 19, 2026

    Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — January 18, 2026   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to ...

    View more
  7. December 29, 2025

    Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

    Shanghai, CN, Cambridge, MA, Rotterdam, NL, – December 28, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical comp...

    View more
  8. December 17, 2025

    Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — December 16, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committ...

    View more
  9. November 24, 2025

    Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — November 23, 2025   Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a g...

    View more
  10. November 07, 2025

    Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — November 7, 2025   Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a gl...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG